Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note issued on Tuesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

Evoke Pharma stock opened at $3.96 on Tuesday. Evoke Pharma has a fifty-two week low of $3.44 and a fifty-two week high of $12.32. The stock has a market cap of $5.88 million, a PE ratio of -0.36 and a beta of 0.16. The firm’s 50-day simple moving average is $4.65 and its 200 day simple moving average is $4.76.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Evoke Pharma stock. Nantahala Capital Management LLC raised its stake in Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 148,194 shares of the specialty pharmaceutical company’s stock after acquiring an additional 91,945 shares during the quarter. Nantahala Capital Management LLC owned approximately 9.95% of Evoke Pharma worth $655,000 as of its most recent filing with the Securities & Exchange Commission.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.